<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962724</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 1143-108</org_study_id>
    <nct_id>NCT04962724</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants</brief_title>
  <official_title>A Phase 1, Open-label, 2-part, Single-dose Study of the Absorption, Metabolism, and Excretion of Oral [14C]-Xevinapant, and Absolute Oral Bioavailability of Xevinapant in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine absorption, metabolism, and excretion of a single&#xD;
      oral dose of [14C]-xevinapant. This information will enable assessment of absorption and&#xD;
      clearance mechanisms of [14C]-xevinapant as well as identify metabolites. In addition, the&#xD;
      study will allow to determine absolute bioavailability of xevinapant and understand its&#xD;
      intravenous pharmacokinetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">November 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance Recovery Measured Through Total Radioactivity Excreted in Expired Air, Urine and Feces</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Concentration-Time Curve From Time Zero to Infinity (AUC0-infinity); Time 0 to 24 Hours (AUC0-24); Time 0 to Last Quantifiable Concentration (AUC0-last) of Total Radioactivity in Blood and Plasma, and of Xevinapant and Metabolite in Plasma</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Total Radioactivity in Blood and Plasma, and of Xevinapant and Metabolite in Plasma</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Blood and Plasma, and of Xevinapant and Metabolite in Plasma</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life (T1/2) of Total Radioactivity in Blood and Plasma, and of Xevinapant and Metabolite in Plasma</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (Vz/F) of Total Radioactivity in Blood and Plasma, and of Xevinapant and Metabolite in Plasma</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Clearance (CL/F) of Total Radioactivity in Blood and Plasma and of Xevinapant and Metabolite in Plasma</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of Total Radioactivity, Xevinapant and Metabolite</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Xevinapant Metabolite Concentrations in Urine, Feces, Blood and Plasma</measure>
    <time_frame>Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Bioavailability (F) of Xevinapant in Plasma</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>Absolute Bioavailability (F) = (AUC0-infinity [oral]/ dose [oral]) /(AUC0-infinity [IV]/ dose [IV])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood to Plasma Ratio of Xevinapant and Metabolite</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Protein Binding Expressed as Fraction unbound, fu of Xevinapant</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Clinically significant Laboratory Abnormalities</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Clinically significant 12-lead ECG Parameters Abnormalities</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Clinically significant Vital Signs Abnormalities</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Clinically significant Physical Examination Abnormalities</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Radiolabeled Xevinapant Oral Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive:&#xD;
• single oral dose of [14C]-xevinapant, as an oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiolabeled Xevinapant Intravenous Solution + Xevinapant Oral Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive:&#xD;
• single oral dose of xevinapant, as an oral solution followed by an IV bolus of [14C]-xevinapant, solution for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiolabelled Xevinapant 200 mg (Oral Solution)</intervention_name>
    <description>[14C]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) [3.7 megabecquerel (MBq)] in fasted conditions.</description>
    <arm_group_label>Radiolabeled Xevinapant Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiolabelled Xevinapant 100 μg (IV Solution)</intervention_name>
    <description>100 μg [14C]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi [7.4 kilobecquerel (kBq)].</description>
    <arm_group_label>Radiolabeled Xevinapant Intravenous Solution + Xevinapant Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xevinapant 200 mg (Oral Solution)</intervention_name>
    <description>Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions</description>
    <arm_group_label>Radiolabeled Xevinapant Intravenous Solution + Xevinapant Oral Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1: Males of any race, between 35 and 65 years of age, inclusive. Part 2: Males of&#xD;
             any race, between 18 and 65 years of age, inclusive&#xD;
&#xD;
          -  Body mass index between 18.0 and 30.0 kilograms per meter square (kg/m^2), inclusive&#xD;
&#xD;
          -  Weight between 50 kilograms (kg) and 110 kg, inclusive&#xD;
&#xD;
          -  History of a minimum of 1 bowel movement per day.&#xD;
&#xD;
          -  Willing to adhere to the prohibitions and restrictions specified in the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee)&#xD;
&#xD;
          -  History of alcohol consumption of &gt;21 units per week. One unit of alcohol equals 12&#xD;
             ounce (oz) [360 millilitre (mL)] beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 90 days prior to dosing, or less than 5 times the&#xD;
             half-life, whichever is longer, prior to administration of study drug&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Have participated in any clinical study involving a radiolabeled investigational&#xD;
             product within 12 months prior to check-in.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Debiopharm International S.A</last_name>
    <phone>+41 21 321 01 11</phone>
    <email>clinicaltrials@debiopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Labcorp Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Israel, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xevinapant</keyword>
  <keyword>Absorption, Distribution, Metabolism and Excretion (ADME)</keyword>
  <keyword>Mass balance</keyword>
  <keyword>Absolute bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

